Kirkland & Ellis advised Galderma, an emerging pure-play dermatology category leader, on a private placement of approximately $1 billion for newly issued shares, from a group consisting of current shareholders, new investors, as well as management. The transaction is expected to close in the coming weeks and an Initial Public Offering remains the likely next step in Galderma’s ambition to become the leading dermatology company in the world. Read Galderma’s press release The Kirkland team was led by corporate partners Roger Johnson, Aneeq Durrani, Andreas Philipson and Adrian Duncan and associates Jamie Gordon, George Rawlinson and Usman Malik; and tax partners Timothy Lowe and Cian O’Connor.